Bottom line
RYCFX vs BIB: the short answer
RYCFX (Biotechnology Fund) and BIB (ProShares Ultra Nasdaq Biotechnology) are both mutual funds.
But BIB is far broader, holding 267 positions to 74 for RYCFX, so beyond the top names it adds exposure RYCFX doesn't have.
BIB is cheaper at 0.95% vs 2.38% — a difference of $143 a year per $10,000 invested.
Over five years, RYCFX returned +3.0% a year vs −1.0% for BIB.
Updated Nov 19, 2026
RYCFX vs BIB side by side
| RYCFX | BIB | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Guggenheim | ProShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 2.38% | 0.95% |
| Annual cost per $10k | $238 | $95 |
| 10-yr cost on $10k (prospectus) | $2,763 | $1,401 |
| Max front load | 0% | None |
| 12b-1 fee | 1% | — |
| 1-yr return | +28.4% | +59.3% |
| 5-yr return (annualized) | +3.0% | −1.0% |
| 10-yr return (annualized) | +4.8% | +1.4% |
| Best quarter | +28.0% | +56.2% |
| Worst quarter | −22.7% | −42.7% |
| Net assets (fund) | $136.8M | $73.7M |
| Number of holdings | 74 | 267 |
| Portfolio turnover | 75% | 29% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RYCFX | BIB | Difference |
|---|---|---|---|
| 2025 | +29.4% | +59.3% | −29.9% |
| 2024 | −1.7% | −10.0% | +8.3% |
| 2023 | +5.0% | −1.3% | +6.3% |
| 2022 | −13.9% | −28.6% | +14.7% |
| 2021 | +0.8% | −5.9% | +6.7% |
| 2020 | +20.9% | +39.7% | −18.9% |
| 2019 | +23.8% | +45.5% | −21.7% |
| 2018 | −9.9% | −24.4% | +14.5% |
| 2017 | +28.4% | +40.8% | −12.3% |
| 2016 | −20.3% | −44.2% | +23.9% |
Source: Fund prospectus bar charts
Holdings overlap
17 of RYCFX's top 25 holdings also appear in BIB's top 25.
| Holding | RYCFX | BIB |
|---|---|---|
| Amgen Inc | 5.05% | 4.48% |
| Gilead Sciences Inc | 4.49% | 4.66% |
| Vertex Pharmaceuticals Inc | 4.32% | 4.65% |
| Regeneron Pharmaceuticals Inc | 2.93% | 3.21% |
| Revolution Medicines Inc | 2.48% | 1.57% |
| Alnylam Pharmaceuticals Inc | 2.36% | 2.01% |
| Moderna Inc | 2.15% | 0.94% |
| Biogen Inc | 2.13% | 1.44% |
| Royalty Pharma Plc | 2.01% | 1.20% |
| Illumina Inc | 1.94% | 1.25% |
| Insmed Inc | 1.79% | 1.16% |
| United Therapeutics Corp | 1.72% | 1.22% |
| Guardant Health Inc | 1.72% | 0.85% |
| Roivant Sciences Ltd | 1.66% | 1.08% |
| Incyte Corp | 1.62% | 0.97% |
Source: SEC Form N-PORT
RYCFX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
FAQ
What is the difference between RYCFX and BIB?
Which is cheaper, RYCFX or BIB?
Should I own both RYCFX and BIB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.